TABLE 4.
Multivariate analysis of survival rates for entire cohort by Cox regression
| Variables | OS | PFS | LPFS | DMFS | ||||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | |
| Gender (male as ref.) | 0.15 (0.04‐0.59) | .006 | 0.33 (0.15‐0.71) | .005 | 0.2 (0.55‐0.73) | .014 | 0.66 (0.21‐2.01) | .46 |
| Age (≤49 y vs >49 y) | 2.91 (0.91‐9.33) | .07 | 1.3 (0.64‐2.69) | .49 | 1.78 (0.61‐5.26) | .29 | 0.91 (0.27‐3.05) | .87 |
| Histology (others as ref.) | ||||||||
| Sarcoma | 9.3 (2.56‐33.75) | .001 | 2.82 (1.21‐6.56) | .016 | 1.71 (0.51‐5.73) | .39 | 5.01 (1.25‐20.1) | .02 |
| Melanoma | 17.4 (3.1‐97.39) | .001 | 6.3 (2.2‐18.07) | .001 | 0 | .98 | 8.49 (1.61‐44.6) | .01 |
| N categories (N0 vs N1‐3) | 1.63 (0.48‐5.58) | .44 | 1.62 (0.58‐4.48) | .36 | 0.88 (0.16‐4.97) | .89 | 1.62 (0.4‐6.6) | .5 |
| GTV (continuous variable) | 1.0 (0.25‐4.06) | .058 | 1.0 (1.0‐1.02) | .13 | 1.0 (0.98‐1.01) | .97 | 1.01 (1.0‐1.03) | .03 |
| Radiotherapy (RT‐naive vs re‐irradiation) | 5.69 (1.0‐35.51) | .051 | 1.96 (0.68‐5.63) | .21 | 1.79 (0.48‐6.61) | .38 | 0.48 (0.04‐5.8) | .57 |
| Surgery (surgery vs without surgery + biopsy) | 0.37 (0.1‐1.41) | .15 | 0.75 (0.34‐1.64) | .47 | 0.9 (0.3‐2.7) | .85 | 1.1 (0.3‐4.03) | .89 |
| BED (continuous variable) | 1.07 (0.93‐1.22) | .37 | 1.0 (0.93‐1.1) | .84 | 1.0 (0.89‐1.13) | .92 | 1.0 (0.86‐1.13) | .82 |
Abbreviations: BED, biological equivalent dose; DMFS, distant metastasis‐free survival; HR, Hazard ratio; LPFS, local progression‐free survival; OS, overall survival; PFS, progression‐free survival.
Statistically significant differences indicated in bold type.